| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | AZD6244 | UHNBreast | pan-cancer | AAC | -0.26 | 0.4 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |